1
|
Roa F, González I, Savic D, Van Goubergen J, Santer F, Puhr M, Toledo J, Skvortsova I, Culig Z, Klocker H. Role of mitochondrial dynamics in tumorigenic potential and docetaxel resistance in prostate cancer. EUR UROL SUPPL 2022. [DOI: 10.1016/s2666-1683(22)01948-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022] Open
|
2
|
Hoefer J, Gruber M, Weber A, Kharaishvili G, Bouchal J, Skvortsova I, Culig Z, Puhr M. Knockdown of PIAS1 increases the sensitivity to radiotherapy in breast cancer. Eur J Cancer 2018. [DOI: 10.1016/s0959-8049(18)30610-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
3
|
Baro M, de Llobet LI, Figueras A, Skvortsova I, Mesia R, Balart J. Dasatinib worsens the effect of cetuximab in combination with fractionated radiotherapy in FaDu- and A431-derived xenografted tumours. Br J Cancer 2014; 111:1310-8. [PMID: 25077442 PMCID: PMC4183853 DOI: 10.1038/bjc.2014.432] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 06/02/2014] [Accepted: 07/09/2014] [Indexed: 12/24/2022] Open
Abstract
Background: Cetuximab is often combined with radiotherapy in advanced SCCHN. Alternative routes bypassing inhibition of EGFR with cetuximab may overshadow the efficacy of this combination. We undertook this study to investigate a possible role of dasatinib in this scenario. Methods: The SCC5, SCC25, SCC29, FaDu and A431 cell lines were assessed in vitro for cell proliferation under cetuximab and dasatinib treatments. In FaDu and A431 cells, dasatinib plus cetuximab resulted in higher proliferation than cetuximab alone. Then, FaDu and A431 cells were implanted into subcutaneous tissue of athymic mice that were irradiated with 30 Gy in 10 fractions over 2 weeks, and treated with cetuximab and dasatinib. Tumour growth, DNA synthesis and angiogenesis were determined. The EGFR, RAS-GTP activity, phosphorylated AKT, ERK1/2, SRC protein levels and VEGF secretion were determined in vitro. Results: The addition of dasatinib to cetuximab and radiotherapy increased tumour growth, DNA synthesis and angiogenesis that were associated with RAS, AKT and ERK1/2 activation, and SRC inhibition in FaDu and A431 cells. Conclusions: In xenografts derived from these two cell lines, dasatinib did not improve the efficacy of cetuximab combined with radiotherapy. On the contrary, it worsened tumour control achieved by the combination of these two treatments.
Collapse
Affiliation(s)
- M Baro
- Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain
| | - L I de Llobet
- Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain
| | - A Figueras
- Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain
| | - I Skvortsova
- Department of Therapeutic Radiology and Oncology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria
| | - R Mesia
- Department of Medical Oncology, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain
| | - J Balart
- 1] Laboratory of Translational Research, Catalan Institute of Oncology, Avda. Gran de L'Hospitalet 199-203, 08907 L'Hospitalet de Llobregat, Spain [2] Department of Radiation Oncology, Hospital de la Santa Creu i Sant Pau, Sant Antoni Maria Claret 167, 08025 Barcelona, Spain
| |
Collapse
|
4
|
Skvortsova I, Skvortsov S, Haidenberger A, Devries A, Nevinny-Stickel M, Saurer M, Lukas P, Seppi T. Effects of Paclitaxel and Docetaxel on EGFR-Expressing Human Carcinoma Cells Under Normoxic Versus Hypoxic ConditionsIn Vitro. J Chemother 2013; 16:372-80. [PMID: 15332713 DOI: 10.1179/joc.2004.16.4.372] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Human malignant tumors, such as non-small lung, breast, ovarian, head and neck, prostate, stomach and colorectal cancers express a number of growth factor receptors (e.g. EGFR or EGFR family members) that are regulated by tumor hypoxia and contribute to tumor growth and failure of cytotoxic therapy. Paclitaxel and docetaxel are indispensable substances in the treatment of these tumors. Despite the active clinical use of taxanes, little is known about their cytotoxic activity under hypoxia. The aim of the present work was to compare the cytotoxic effect of taxanes, paclitaxel and docetaxel on the EGFR-expressing carcinoma cell lines A431, MDA-MB-231 and NCI-H358 under normoxic and hypoxic conditions. The two taxanes caused different cell cycle distribution and varying aneuploid cell formation under hypoxia. EGFR-overexpressing carcinoma cells showed hypoxia to severely affect the cytotoxicity of paclitaxel, whereas docetaxel preserved its tumor cell-killing activity even at lowest concentrations (0.5 nM), as was observed for both taxanes under normoxia.
Collapse
Affiliation(s)
- I Skvortsova
- Department of Radiotherapy-Radiooncology, Innsbruck Medical University, Anichstr. 35, A-6020 Innsbruck, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
5
|
Skvortsova I, Skvortsov S, Jimenez C, Knol J, Dudas J, Eichberger P, Schiestl B, Lukas P. 133 Rac1-related Signaling Pathways Contributing to Head and Neck Carcinoma Radioresistance. Eur J Cancer 2012. [DOI: 10.1016/s0959-8049(12)71931-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
6
|
Skvortsov S, Skvortsova I, Sarg B, Lindner H, Lukas P, Hilbe W, Zwierzina H. 506 POSTER Cetuximab-induced thymidylate synthase inhibition is associated with EGFR expression. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)70445-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
7
|
von Guggenberg E, Dietrich H, Skvortsova I, Gabriel M, Virgolini IJ, Decristoforo C. 99mTc-labelled HYNIC-minigastrin with reduced kidney uptake for targeting of CCK-2 receptor-positive tumours. Eur J Nucl Med Mol Imaging 2007; 34:1209-18. [PMID: 17308920 DOI: 10.1007/s00259-006-0348-3] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2006] [Accepted: 11/17/2006] [Indexed: 10/23/2022]
Abstract
PURPOSE Different attempts have been made to develop a suitable radioligand for targeting CCK-2 receptors in vivo, for staging of medullary thyroid carcinoma (MTC) and other receptor-expressing tumours. After initial successful clinical studies with [DTPA(0),D: Glu(1)]minigastrin (DTPA-MG0) radiolabelled with (111)In and (90)Y, our group developed a (99m)Tc-labelled radioligand, based on HYNIC-MG0. A major drawback observed with these derivatives is their high uptake by the kidneys. In this study we describe the preclinical evaluation of the optimised shortened peptide analogue, [HYNIC(0),D: Glu(1),desGlu(2-6)]minigastrin (HYNIC-MG11). METHODS (99m)Tc labelling of HYNIC-MG11 was performed using tricine and EDDA as coligands. Stability experiments were carried out by reversed phase HPLC analysis in PBS, PBS/cysteine and plasma as well as rat liver and kidney homogenates. Receptor binding and cell uptake experiments were performed using AR4-2J rat pancreatic tumour cells. Animal biodistribution was studied in AR4-2J tumour-bearing nude mice. RESULTS Radiolabelling was performed at high specific activities and radiochemical purity was >90%. (99m)Tc-EDDA-HYNIC-MG11 showed high affinity for the CCK-2 receptor and cell internalisation comparable to that of (99m)Tc-EDDA-HYNIC-MG0. Despite high stability in solution, a low metabolic stability in rat tissue homogenates was found. In a nude mouse tumour model, very low unspecific retention in most organs, rapid renal excretion with reduced renal retention and high tumour uptake were observed. CONCLUSION (99m)Tc-EDDA-HYNIC-MG11 shows advantages over (99m)Tc-EDDA-HYNIC-MG0 in terms of lower kidney retention with unchanged uptake in tumours and CCK-2 receptor-positive tissue. However, the lower metabolic stability and impurities formed in the labelling process still leave room for further improvement.
Collapse
Affiliation(s)
- E von Guggenberg
- Clinical Department of Nuclear Medicine, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria.
| | | | | | | | | | | |
Collapse
|
8
|
Skvortsova I, Skvortsov S, Popper B, Saurer M, Pleiman C, Lukas P. 145 The new microtubule-interfering compound mpi-0441138 acts as radiosensitizing agent in cancer cells in vitro. Radiother Oncol 2006. [DOI: 10.1016/s0167-8140(06)80624-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
9
|
Skvortsov S, Skvortsova I, Sarg B, Loeffler-Ragg J, Lindner H, Lukas P, Tabernero J, Zwierzina H. Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line. Apoptosis 2006; 10:1175-86. [PMID: 16151650 DOI: 10.1007/s10495-005-1322-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
The epidermal growth factor receptor (EGFR) is overexpressed in the majority of colorectal carcinomas and represents a target for therapeutic interventions with signal transduction inhibitors. We investigated the ability of CI-1033 to induce apoptosis and inhibition of proliferation in the colorectal cancer cell lines DiFi and Caco-2, which both express high levels of EGFR. While in Caco-2 cells CI-1033 treatment at a concentration 0.1 microM for 72 hours demonstrated only antiproliferative (53.7 +/- 4.3%) but no pro-apoptotic effects, treatment of DiFi cells resulted in a reduced proliferation rate (31.4 +/- 3.1%) and in apoptosis (44.2 +/- 8.9%). In order to define proteins involved in the regulation of apoptosis, we aimed to determine differences in the proteome profile of both cell lines before and after treatment with CI-1033. Cellular proteins were analyzed by 2-D gel electrophoresis followed by computational image analysis and mass spectrometry. Our data show that DiFi cells differ from Caco-2 cells in nine significantly upregulated proteins, and their potential role in apoptosis is described. We demonstrate that induction of apoptosis was triggered via caspase-independent pathways. Overexpression of leukocyte elastase inhibitor (LEI) and translocation of cathepsin D to the cytosol accompanied by upregulation of other defined proteins resulted in Bax-independent AIF translocation from mitochondria into the nucleus and apoptosis. Definition of these proteins can pave the way for functional studies and contribute to a better understanding of the effects of CI-1033 and the pathways of caspase-independent cell death.
Collapse
Affiliation(s)
- S Skvortsov
- Department of Internal Medicine, Innsbruck Medical University, Anichstrasse 35, A-6020 Innsbruck, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Skvortsova I, Seppi T, Haidenberger A, DeVries A, Skvortsov S, Geiler H, Sauer M, Lukas P. 480 Comparison of in vitro growth-inhibitory activity of paclitaxel and docetaxel on squamous cell carcinoma under normoxic and hypoxic conditions during irradiation. EJC Suppl 2003. [DOI: 10.1016/s1359-6349(03)90512-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
11
|
Skvortsova I, Igitov V, Seppi T, Zwierzina H, Popper B, Lukas P. Modulation of CTL-activity by TNF-a during postoperative radiotherapy in colorectal cancer patients. Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81326-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
12
|
Churilova L, Skvortsova I, Lazarev A, Lubennikov V, Baluyeva N, Beljakov S, Markosjan S, Trotsko D, Pustoshilova N, Grechcko V. Cytokines in anticancer therapy in advanced and metastatic breast cancer. Eur J Cancer 1999. [DOI: 10.1016/s0959-8049(99)81730-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
13
|
Skvortsova I, Iazarev A, Lubennikov V, Suslov Y, Baluyeva N, Belonozhka A, Pustoshilova N, Shpigotski A. Early postoperative intraperitoneal chemo-immunotherapy after curative gastrectomy for stomach cancer. Eur J Cancer 1997. [DOI: 10.1016/s0959-8049(97)86162-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|